192 related articles for article (PubMed ID: 31675179)
1. Cell-Based Optimization of Covalent Reversible Ketoamide Inhibitors Bridging the Unprimed to the Primed Site of the Proteasome β5 Subunit.
Stubba D; Bensinger D; Steinbacher J; Proskurjakov L; Salcedo Gómez Á; Schmidt U; Roth S; Schmitz K; Schmidt B
ChemMedChem; 2019 Dec; 14(23):2005-2022. PubMed ID: 31675179
[TBL] [Abstract][Full Text] [Related]
2. A new class of α-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities.
Wang J; Liang B; Chen Y; Fuk-Woo Chan J; Yuan S; Ye H; Nie L; Zhou J; Wu Y; Wu M; Huang LS; An J; Warshel A; Yuen KY; Ciechanover A; Huang Z; Xu Y
Eur J Med Chem; 2021 Apr; 215():113267. PubMed ID: 33639344
[TBL] [Abstract][Full Text] [Related]
3. α-Keto phenylamides as P1'-extended proteasome inhibitors.
Voss C; Scholz C; Knorr S; Beck P; Stein ML; Zall A; Kuckelkorn U; Kloetzel PM; Groll M; Hamacher K; Schmidt B
ChemMedChem; 2014 Nov; 9(11):2557-64. PubMed ID: 25087721
[TBL] [Abstract][Full Text] [Related]
4. Development of peptidomimetic boronates as proteasome inhibitors.
Micale N; Ettari R; Lavecchia A; Di Giovanni C; Scarbaci K; Troiano V; Grasso S; Novellino E; Schirmeister T; Zappalà M
Eur J Med Chem; 2013 Jun; 64():23-34. PubMed ID: 23639651
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
Blackburn C; Gigstad KM; Hales P; Garcia K; Jones M; Bruzzese FJ; Barrett C; Liu JX; Soucy TA; Sappal DS; Bump N; Olhava EJ; Fleming P; Dick LR; Tsu C; Sintchak MD; Blank JL
Biochem J; 2010 Sep; 430(3):461-76. PubMed ID: 20632995
[TBL] [Abstract][Full Text] [Related]
6. Systematic comparison of peptidic proteasome inhibitors highlights the α-ketoamide electrophile as an auspicious reversible lead motif.
Stein ML; Cui H; Beck P; Dubiella C; Voss C; Krüger A; Schmidt B; Groll M
Angew Chem Int Ed Engl; 2014 Feb; 53(6):1679-83. PubMed ID: 24403024
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome.
Sun Q; Zhou T; Xi D; Li X; Lü Z; Xu F; Wang C; Niu Y; Xu P
Eur J Med Chem; 2020 Apr; 192():112160. PubMed ID: 32146375
[TBL] [Abstract][Full Text] [Related]
8. Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads.
Kollár L; Gobec M; Proj M; Smrdel L; Knez D; Imre T; Gömöry Á; Petri L; Ábrányi-Balogh P; Csányi D; Ferenczy GG; Gobec S; Sosič I; Keserű GM
Cells; 2021 Dec; 10(12):. PubMed ID: 34943940
[TBL] [Abstract][Full Text] [Related]
9. An historic perspective of proteasome inhibition.
Esseltine DL; Mulligan G
Semin Hematol; 2012 Jul; 49(3):196-206. PubMed ID: 22726542
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic unsaturated electrophilic compounds commonly target the ubiquitin proteasome system.
Selvaraju K; Mofers A; Pellegrini P; Salomonsson J; Ahlner A; Morad V; Hillert EK; Espinosa B; Arnér ESJ; Jensen L; Malmström J; Turkina MV; D'Arcy P; Walters MA; Sunnerhagen M; Linder S
Sci Rep; 2019 Jul; 9(1):9841. PubMed ID: 31285509
[TBL] [Abstract][Full Text] [Related]
11. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells.
Kraus M; Rückrich T; Reich M; Gogel J; Beck A; Kammer W; Berkers CR; Burg D; Overkleeft H; Ovaa H; Driessen C
Leukemia; 2007 Jan; 21(1):84-92. PubMed ID: 17024115
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation.
Weyburne ES; Wilkins OM; Sha Z; Williams DA; Pletnev AA; de Bruin G; Overkleeft HS; Goldberg AL; Cole MD; Kisselev AF
Cell Chem Biol; 2017 Feb; 24(2):218-230. PubMed ID: 28132893
[TBL] [Abstract][Full Text] [Related]
13. Targeting the ubiquitin proteasome system in haematological malignancies.
Crawford LJ; Irvine AE
Blood Rev; 2013 Nov; 27(6):297-304. PubMed ID: 24183816
[TBL] [Abstract][Full Text] [Related]
14. Development of a new class of proteasome inhibitors with an epoxyketone warhead: Rational hybridization of non-peptidic belactosin derivatives and peptide epoxyketones.
Kawamura S; Unno Y; Asai A; Arisawa M; Shuto S
Bioorg Med Chem; 2014 Jun; 22(12):3091-5. PubMed ID: 24814885
[TBL] [Abstract][Full Text] [Related]
15. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
[TBL] [Abstract][Full Text] [Related]
16. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
17. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
Franke NE; Niewerth D; Assaraf YG; van Meerloo J; Vojtekova K; van Zantwijk CH; Zweegman S; Chan ET; Kirk CJ; Geerke DP; Schimmer AD; Kaspers GJ; Jansen G; Cloos J
Leukemia; 2012 Apr; 26(4):757-68. PubMed ID: 21941364
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
Niroula D; Hallada LP; Le Chapelain C; Ganegamage SK; Dotson D; Rogelj S; Groll M; Tello-Aburto R
Eur J Med Chem; 2018 Sep; 157():962-977. PubMed ID: 30165344
[TBL] [Abstract][Full Text] [Related]
19. The immunoproteasome as a therapeutic target for hematological malignancies.
Miller Z; Lee W; Kim KB
Curr Cancer Drug Targets; 2014; 14(6):537-48. PubMed ID: 25059201
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine.
Jorda R; Dušek J; Řezníčková E; Pauk K; Magar PP; Imramovský A; Kryštof V
Eur J Med Chem; 2017 Jul; 135():142-158. PubMed ID: 28441582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]